1679-P: Current State of Type 1 Diabetes in Adults: Data from the Canadian LMC Diabetes Registry
Bibliographic record
Abstract
Population-based data regarding the current state of T1D care remains limited. This cross-sectional study describes adults with T1D in the LMC Diabetes Registry, comprised of the longitudinal health data of >50 Endocrinology practices across 3 Canadian provinces. A cohort of 3386 adults under care ≥6 months were included: age 44.4 ± 15.3 years; age at diagnosis 22.6 ± 14.3 years; 54.8% male (Table). The majority use analogue insulin (98.4% basal and 99.8% bolus insulin use), 36.6% use an insulin pump and 12.8% use a CGM device. Mean A1C at referral was 8.6 ± 1.8%; current mean A1C was lower at 8.1 ± 1.5%. Although 23.5% were at target A1C ≤ 7.0%, a persistent A1C > 9.0% was seen in 21.6%. Mean A1C was highest among young adults. Over half (56%) reported >1 weekly episodes of hypoglycemia; 3.3% reported severe hypoglycemia in the prior year. In CGM users (n=352, mean A1C 7.7 ± 1.3%), mean glucose was 9.4 ± 2.0 mmol/L and mean CV was 38.5 ± 8.3%. Time in range was 54.4 ± 17.8% and time in hypoglycemia was 6.3 ± 6.1%. Common comorbidities included mental health (9.8%), microvascular (retinopathy 14.4%, CKD 8.2%, nephropathy 24.5%, clinically significant neuropathy 6.5%) and macrovascular (5.5%) disorders. Despite care from diabetes specialists, operating with advanced resources, and within a public health system, the majority of Canadian adults with T1D are not reaching glycemic targets and under-use available advanced technologies. Disclosure R. Aronson: Research Support; Self; AstraZeneca, Becton, Dickinson and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novo Nordisk Inc., Sanofi, Senseonics. R.E. Brown: None. A. Abitbol: Advisory Panel; Self; Merck & Co., Inc., Novo Nordisk Inc. Research Support; Self; Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc., JDRF, Lexicon Pharmaceuticals, Inc., Pfizer Inc., Senseonics, Xeris Pharmaceuticals, Inc., Zealand Pharma A/S. Speaker's Bureau; Self; AstraZeneca, Sanofi. R. Goldenberg: Advisory Panel; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi. O. Ajala: None. J. Yale: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi. Research Support; Self; AstraZeneca, Bayer Canada, Mylan. Speaker's Bureau; Self; Abbott, AstraZeneca, Bayer Canada, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi, Takeda Canada. Z. Yared: None. Funding Sanofi Canada
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.003 | 0.008 |
| Science and technology studies | 0.002 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.007 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".